Fermenta Biotech Peer Comparison

NSE: FERMENTA | BSE: 506414

₹509.90

₹23.65 (4.86%)

As on 28-Aug-2026IST

Market cap

₹1,501 Cr

Revenue (TTM)

₹511 Cr

P/E Ratio

24.8

P/B Ratio

3.6

Div. Yield

0.7 %

Edit

	Fermenta Biotech	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Market cap (₹ Cr)	1,501	21,501	19,125	18,253	17,766
Revenue (₹ Cr)	511	2,570	2,287	3,230	2,432
Net Profit (₹ Cr)	58.19	735.15	678.07	666.92	169.62
Net Margin (%)	11.00	26.88	28.10	20.60	6.90
RoE (%)	13.91	19.16	19.73	18.75	20.76
Price to Earnings	24.82	29.25	28.74	28.35	104.74
Price-To-Book	3.64	4.88	5.08	4.51	19.65

Income Statement (₹ Cr)

	Fermenta Biotech	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Operating Revenue	525.43	2,519.65	1,937.47	2,893.64	2,275.58
Total Income	547.81	2,707.60	2,033.90	2,912.00	2,304.07
Total Expenditure	424.47	1,615.47	1,290.54	1,876.44	2,013.55
EBITDA	100.95	904.18	646.93	1,017.20	262.03
Depreciation	21.70	57.73	65.96	315.46	28.58
EBIT	79.26	846.45	580.97	701.74	233.45
Interest	12.66	9.57	0.61	231.29	4.49
Other Income	22.39	187.95	96.43	18.36	28.49
Exceptional Items	6.88	-49.16	--	--	-5.25
Profit before Tax	95.86	975.67	676.78	488.87	252.20
Provision for Tax	25.61	253.24	135.69	114.20	64.68
Profit after Tax	70.25	722.43	541.09	374.67	187.52

	Fermenta Biotech	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Shareholder's Funds	406.21	4,202.90	2,850.49	2,854.36	872.79
Minority Interest	-5.67	--	35.90	417.40	--
Non-Current Liabilities	20.26	19.19	13.24	2,100.97	394.49
Current Liabilities	208.77	627.48	305.99	1,489.55	1,109.50
Total Liabilities	647.94	4,921.88	3,207.85	6,862.28	2,414.58

	Fermenta Biotech	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Non-Current Assets	241.56	1,046.35	1,071.67	5,531.13	509.16
Current Assets	388.02	3,803.22	2,133.95	1,331.15	1,859.88
Total Assets	647.94	4,921.88	3,207.85	6,862.28	2,414.58
Total Debt*	108.89	2.50	0.55	2,421.66	0.00
Net Current Assets	179.25	3,175.74	1,827.96	-158.40	750.38
Contingent Liabilities	1.63	370.49	0.64	64.29	121.23

	Fermenta Biotech	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Cash From Operating Activities	92.83	967.57	432.37	1,065.01	-15.14
Cash Flow from Investing Activities	-43.00	-561.67	-334.73	-79.97	18.69
Cash from Financing Activities	-42.29	-798.31	-38.32	-881.32	-91.97
Net Cash Inflow / Outflow	7.55	-392.41	59.32	103.72	-88.42

	Fermenta Biotech	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
ROCE (%)	21.99	23.39	26.22	13.59	31.24
ROE (%)	18.36	17.16	21.72	13.81	23.02
ROA (%)	11.13	14.91	18.37	5.48	8.90
EBIT Margin (%)	23.47	43.34	38.37	35.79	12.77
Net Margin (%)	12.82	26.68	26.60	12.87	8.14
Cash Profit Margin (%)	17.50	29.72	31.33	23.22	9.47

	Fermenta Biotech	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Revenue Growth (%)	11.92	10.45	14.37	44.02	32.59
EBIT Growth (%)	0.83	19.68	20.21	48.22	-1.38
Net Profit Growth (%)	-8.05	-5.88	17.27	-5.65	62.02
EPS Growth (%)	-5.01	-5.88	17.25	-10.39	62.02
Book Value Growth (%)	11.21	-0.34	23.77	10.19	13.51

	Fermenta Biotech	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Price / Earnings	12.75	29.89	28.38	54.83	103.45
Price / Book Value	2.27	5.14	5.52	6.78	22.39
Dividend Yield (%)	1.18	1.59	0.30	0.52	0.46
EV/EBITDA	7.96	16.93	19.78	20.75	65.23
Market Cap (₹ Cr)	914.72	21,592.90	15,219.80	19,292.77	19,398.64

	Fermenta Biotech	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Debt to Equity	0.27	0.00	0.00	0.85	0.00
Short term debt to equity ratio	0.23	0.00	0.00	0.14	--
Current Ratio	1.86	6.06	6.97	0.89	1.68
Quick Ratio	1.13	5.31	5.88	0.67	0.75
Interest Coverage	8.57	102.95	1,110.48	3.11	57.17

	Fermenta Biotech	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Debtors to sales (%)	21.24	7.22	32.65	15.85	9.39
Asset Turnover	0.83	0.54	0.66	0.43	1.08
Receivable days	71.83	26.06	110.70	54.07	31.88
Inventory Days	95.93	65.95	65.86	32.16	126.03
Payable days	147.04	81.01	105.88	140.91	163.79
Cash Conversion Cycle	20.73	11.00	70.68	-54.68	-5.88

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.